Market Closed -
OTC Markets
16:44:58 01/05/2024 BST
5-day change
1st Jan Change
0.006
USD
-32.58%
-10.45%
-80.00%
Sales 2021
-
Sales 2022
-
Capitalization
2.59M
207M
Net income 2021
-6M
-478M
Net income 2022
-2M
-159M
EV / Sales 2021
-
Net Debt
2021
6.59M
525M
Net Debt
2022
8.55M
682M
EV / Sales 2022
-
P/E ratio 2021
-0.11
x
P/E ratio 2022
-0.69
x
Employees
-
Yield 2021 *
-
Yield 2022
-
Free-Float
88.26%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement
01-18
CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer
01-16
CI
Adhera Therapeutics, Inc. Announces Board Resignations
01-16
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-20
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
21/08/23
CI
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding
21/06/23
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
22/05/23
CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
27/04/23
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
31/03/23
CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
30/03/23
CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding
01/03/23
CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding
15/02/23
CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
25/01/23
CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
14/12/22
CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
14/11/22
CI
More news
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)
17/10/23
AQ
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?
10/08/23
PR
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
19/09/22
AQ
ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)
09/09/22
AQ
ADHERA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
25/08/22
AQ
More press releases
1 day -32.58%
1 week -10.45%
Current month -50.00%
1 month -56.20%
3 months -65.71%
6 months -31.03%
Current year -80.00%
More quotes
Managers
Title Age Since
Chief Operating Officer
43
06/07/20
Members of the board
Title Age Since
Director/Board Member
59
09/07/20
Chief Operating Officer
43
06/07/20
More insiders
Date
Price
Change
Volume
01/05/24
0.006
-32.58%
12,130
30/04/24
0.0089
0.00%
4,411
29/04/24
0.0089
0.00%
18,131
26/04/24
0.0089
+18.83%
7,000
24/04/24
0.00749
+11.79%
2,001
Delayed Quote
OTC Markets, May 01, 2024 at 04:44 pm
More quotes
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
More about the company
1st Jan change
Capi.
-80.00% 69.76K -1.65% 104B +6.75% 97.47B +5.71% 22.25B -12.60% 21.68B -9.70% 18.2B -39.98% 17.02B -10.17% 16.36B +6.12% 14.39B +35.47% 12.37B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1